The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s
heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria …

A decade of discovery and development of new anti-malarial medicines has led to a
renewed focus on malaria elimination and eradication. Changes in the way new anti …

Plasmodium vivax is the most widespread human malaria, putting 2.5 billion people at risk of
infection. Its unique biological and epidemiological characteristics pose challenges to …

Most Plasmodium falciparum infections that are detected in community surveys are
characterized by low-density parasitaemia and the absence of clinical symptoms. Molecular …

Plasmodium vivax is an important cause of malaria, associated with a significant public
health burden. Whilst enhanced malaria-control activities have successfully reduced the …

There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and
novel modes of action, to widen the scope of treatment and to overcome emerging drug …

Malaria is a devastating infectious disease that is caused by blood-borne apicomplexan
parasites of the genus Plasmodium. These pathogens have a complex lifecycle, which …

Scale-up of malaria control interventions has resulted in a substantial decline in global
malaria morbidity and mortality. Despite this achievement, there is evidence that current …

Achieving a malaria-free world presents exciting scientific challenges as well as
overwhelming health, equity, and economic benefits. WHO and countries are setting …

Background Primaquine is a key drug for malaria elimination. In addition to being the only
drug active against the dormant relapsing forms of Plasmodium vivax, primaquine is the sole …